Back

ADAR1 Regulates Lipid Remodeling through MDM2 to Dictate Ferroptosis Sensitivity

Kung, C.-P.; Terzich, N. D.; Ilagan, M. X. G.; Prinsen, M. J.; Kaushal, M.; Kladney, R. D.; Weber, J. H.; Mabry, A. R.; Torres, L. S.; Bramel, E. R.; Freeman, E. C.; Sabloak, T.; Cottrell, K. A.; Ryu, S.; Weber, W. M.; Maggi, L.; Shriver, L. P.; Patti, G. J.; Weber, J. D.

2025-01-21 cancer biology
10.1101/2025.01.16.633410 bioRxiv
Show abstract

Triple-negative breast cancer (TNBC), defined by the lack of estrogen, progesterone, and HER2 receptor expressions, is aggressive and lacks targeted treatment options. Adenosine deaminase acting on RNA 1 (ADAR1) has been shown to contribute to TNBC tumorigenesis by modulating an innate immune response. However, little is known about its role in the regulation of metabolic fitness of TNBC. We tested the hypothesis that ferroptosis is an ADAR1-protected vulnerability by showing that ADAR1 knockdown sensitizes TNBC cells to ferroptosis inducers. Lipidomic analyses showed that ADAR1 loss increased the abundance of phospholipids enriched with polyunsaturated fatty acids (PUFA), of which peroxidation is the main driver of ferroptosis. Transcriptomic analyses discovered that the proto-oncogene MDM2 contributes to the lipid remodeling phenotype. A ferroptosis-focused drug screen identified FDA-approved cobimetinib as a drug-repurposing candidate to synergize with ADAR1 loss. This finding supports further basic, pre-clinical, and clinical studies to develop novel therapeutic strategies for TNBC through ADAR1-mediated metabolic regulation.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cell Death & Differentiation
○ 48 papers in training set
Top 0.1%
12.7%
Similar papers in this journal
2
Redox Biology
○ 70 papers in training set
Top 0.1%
11.9%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 17%
11.0%
Similar papers in this journal
4
Cell Reports
○ 1498 papers in training set
Top 3%
7.9%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 26%
4.8%
Similar papers in this journal
6
Science Advances
● 1243 papers in training set
Top 7%
4.5%
50% of probability mass above
7
Cell Chemical Biology
○ 94 papers in training set
Top 0.2%
4.4%
8
Cancer Research
● 130 papers in training set
Top 1%
3.4%
9
Cell Death & Disease
147 papers in training set
Top 0.8%
3.2%
10
iScience
○ 1154 papers in training set
Top 8%
3.1%
11
Communications Biology
○ 993 papers in training set
Top 10%
2.1%
12
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 23%
2.1%
13
Molecular Cell
○ 350 papers in training set
Top 3%
1.9%
14
Cell Death Discovery
○ 58 papers in training set
Top 0.9%
1.1%
15
Cancer Research Communications
● 51 papers in training set
Top 1%
1.1%
16
Developmental Cell
○ 196 papers in training set
Top 3%
1.1%
17
Cell
○ 431 papers in training set
Top 8%
1.1%
18
Cell Metabolism
○ 57 papers in training set
Top 1.0%
1.1%
19
Advanced Science
○ 286 papers in training set
Top 7%
1.1%
20
Nature Cell Biology
○ 118 papers in training set
Top 2%
1.1%
21
The EMBO Journal
○ 309 papers in training set
Top 4%
1.1%
22
Cancer Letters
○ 35 papers in training set
Top 0.9%
1.1%
23
Oncogene
○ 85 papers in training set
Top 2%
1.0%
24
Cancers
○ 213 papers in training set
Top 4%
0.9%
25
ACS Central Science
● 71 papers in training set
Top 2%
0.6%
26
Cell Reports Medicine
○ 153 papers in training set
Top 6%
0.6%
27
Nature Metabolism
○ 69 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.